Pharmaceutical News

RSS

Watson commences shipment of generic Exelon

Watson Pharmaceuticals, Inc. announced today that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic version of Exelon® (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules. Exelon® is used to treat dementia in people with Alzheimer's disease.

1 Jul 2010

AstraZeneca announces new support program for patients on ARIMIDEX

AstraZeneca today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

1 Jul 2010

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

1 Jul 2010

Prasco to sell and distribute authorized generic version of ZEGERID capsules

Prasco Laboratories announced today that it is now shipping the authorized generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules. Authorized generics are generic pharmaceuticals manufactured identically to the brand product and sold under a private label. Under the terms of a distribution and supply agreement with Santarus, Prasco will sell and distribute the capsule form of Omeprazole/Sodium Bicarbonate in 20 mg and 40 mg strengths in the U.S. under the Prasco label.

1 Jul 2010

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

1 Jul 2010

Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010

Preliminary results of a pre-specified subgroup study analysis of patients with diabetes and hypertension demonstrated that the investigational triple combination therapy of olmesartan medoxomil / amlodipine / hydrochlorothiazide (40/10/25 mg) resulted in a statistically significant greater Least Squares mean reduction in blood pressure from baseline at week 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm Hg, P less than or equal to 0.0013) as compared to corresponding dual combination therapy [olmesartan medoxomil (40 mg) / amlodipine (10 mg); olmesartan medoxomil (40 mg) / hydrochlorothiazide (25 mg); or amlodipine (10 mg) and hydrochlorothiazide (25 mg)].

1 Jul 2010

ESMT CA study: Cutting pharmaceutical prices will reduce number of new medications

Cutting pharmaceutical prices will severely reduce the number of new medications making it to market, according to a groundbreaking independent study from ESMT Competition Analysis. For the first time, the study on 'Pharmaceutical Innovation and Pricing Regulation' clearly models and quantifies the direct link between strict regulation and low innovation.

1 Jul 2010

Experts examine corporate websites dedicated to 100 best-selling prescription drugs

Dartmouth Linguistics Professor Lewis Glinert and Jon Schommer, the associate head of the Department of Pharmaceutical Care and Health Systems at the University of Minnesota, have examined the corporate websites dedicated to the 100 best-selling prescription drugs. They found a startling lack of consistency in an industry where advertising standards are regulated by the Food and Drug Administration.

1 Jul 2010

Researchers uncover potential drug treatment for noise-induced hearing loss

Researchers from the University of Auckland, New Zealand, have discovered that a potent new drug restores hearing after noise-induced hearing loss in rats. The landmark discovery found that injection of an agent called 'ADAC', activates adenosine receptors in cochlear tissues, resulting in recovery of hearing function. The finding paves the way for effective non-surgical therapies to restore hearing loss after noise-induced injury. Dr. Srdjan Vlajkovic and his team's work1 is published in a special edition of Springer's journal Purinergic Signalling, focusing on the inner ear.

1 Jul 2010

Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.

1 Jul 2010

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.

1 Jul 2010

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.

1 Jul 2010

Researchers report no increased rate of heart attack in patients taking rosiglitazone

The diabetes drug rosiglitazone has been under intense scrutiny since a 2007 study in the New England Journal of Medicine looked at more than 40 clinical trials and linked the drug's use with increased risk of heart attack and death from heart disease.

1 Jul 2010

Ecolab launches Virasept to treat Clostridium difficile spores

Ecolab Inc. today announced the launch of Virasept, Ecolab's first ready-to-use (no mixing required) hard surface disinfectant approved by the U.S. Environmental Protection Agency to be effective against Clostridium difficile spores.

1 Jul 2010

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome, and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its wholly-owned subsidiary, Biospherics Incorporated, has signed a license agreement with the University of Kentucky Research Foundation (UKRF).

1 Jul 2010

Judge rules for Merck in state Vioxx lawsuit over Medicaid payments

A federal judge ruled in favor of Merck & Co. Tuesday in a lawsuit brought by Louisiana trying to recoup what it paid when Medicaid patients used the company's withdrawn painkiller Vioxx, The Associated Press reports. James R. Dugan II, "the lead attorney representing Louisiana, said his team would be meeting with state officials later this week to discuss appellate possibilities.

1 Jul 2010

pSivida's licensee submits NDA to FDA for Iluvien

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a New Drug Application to the U.S. Food and Drug Administration for Iluvien for Diabetic Macular Edema.

1 Jul 2010

Studies link anti-cholesterol statin drugs to increased risk of anxiety and depression

Scientists are reporting a possible explanation for the symptoms of anxiety and depression that occur in some patients taking the popular statin family of anti-cholesterol drugs, and reported by some individuals on low-cholesterol diets. These symptoms could result from long-term, low levels of cholesterol in the brain, the report suggests. It appears in ACS' weekly journal Biochemistry.

1 Jul 2010

Prasco commences shipments of generic prescription ZEGERID Capsules

Santarus, Inc., a specialty biopharmaceutical company, today announced that pursuant to its distribution and supply agreement with Prasco, LLC, Prasco is commencing shipments of an authorized generic of prescription ZEGERID® (omeprazole/ sodium bicarbonate) Capsules in 20 mg and 40 mg dosage strengths in the U.S. under the Prasco label. ZEGERID is an immediate-release proton pump inhibitor (PPI) approved as a prescription product in the U.S. for the treatment of certain upper gastrointestinal diseases and disorders.

1 Jul 2010

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Fero Industries, Inc. is pleased to announce that it has closed the acquisition of certain intellectual property and other associated rights related to the production, marketing, and distribution of Sucanon, a treatment for Type II diabetes.

1 Jul 2010

Pharmaceutical News

Watson commences shipment of generic Exelon

AstraZeneca announces new support program for patients on ARIMIDEX

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Prasco to sell and distribute authorized generic version of ZEGERID capsules

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010

ESMT CA study: Cutting pharmaceutical prices will reduce number of new medications

Experts examine corporate websites dedicated to 100 best-selling prescription drugs

Researchers uncover potential drug treatment for noise-induced hearing loss

Endo responds to FDA Complete Response letter for FORTESTA NDA

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Ecolab launches Virasept to treat Clostridium difficile spores

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

Judge rules for Merck in state Vioxx lawsuit over Medicaid payments

pSivida's licensee submits NDA to FDA for Iluvien

Studies link anti-cholesterol statin drugs to increased risk of anxiety and depression

Prasco commences shipments of generic prescription ZEGERID Capsules

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News